MedRx Co., Ltd (4586.T)
JPY 84.0
(-3.45%)
JPY 84.0
(-3.45%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 129 Million JPY | -30.48% |
| 2022 | 185.55 Million JPY | 21.2% |
| 2021 | 153.09 Million JPY | 2.15% |
| 2020 | 149.88 Million JPY | 18.17% |
| 2019 | 126.83 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 65.55 Million JPY | -48.59% |
| 2024 Q2 | 45.33 Million JPY | -30.85% |
| 2023 Q3 | 86.42 Million JPY | 53.09% |
| 2023 Q4 | 127.52 Million JPY | 47.56% |
| 2023 Q1 | 81.78 Million JPY | -55.92% |
| 2023 FY | 127.52 Million JPY | -31.28% |
| 2023 Q2 | 56.45 Million JPY | -30.98% |
| 2022 Q3 | 139.23 Million JPY | 0.0% |
| 2022 FY | 185.55 Million JPY | 21.2% |
| 2022 Q4 | 185.55 Million JPY | 33.27% |
| 2021 FY | 153.09 Million JPY | 2.15% |
| 2020 FY | 149.88 Million JPY | 18.17% |
| 2019 FY | 126.83 Million JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 24.98 Billion JPY | 99.484% |
| Takeda Pharmaceutical Company Limited | 7834.78 Billion JPY | 99.998% |
| Sumitomo Pharma Co., Ltd. | 751.37 Billion JPY | 99.983% |
| Shionogi & Co., Ltd. | 164.35 Billion JPY | 99.922% |
| Wakamoto Pharmaceutical Co.,Ltd. | 3.39 Billion JPY | 96.2% |
| Nippon Shinyaku Co., Ltd. | 42.86 Billion JPY | 99.699% |
| Kaken Pharmaceutical Co., Ltd. | 27.86 Billion JPY | 99.537% |
| Eisai Co., Ltd. | 494.82 Billion JPY | 99.974% |
| Morishita Jintan Co., Ltd. | 5.04 Billion JPY | 97.44% |
| Hisamitsu Pharmaceutical Co., Inc. | 61.69 Billion JPY | 99.791% |
| Mochida Pharmaceutical Co., Ltd. | 30.83 Billion JPY | 99.582% |
| Fuso Pharmaceutical Industries,Ltd. | 39.79 Billion JPY | 99.676% |
| Nippon Chemiphar Co., Ltd. | 31.08 Billion JPY | 99.585% |
| Tsumura & Co. | 132.88 Billion JPY | 99.903% |
| Kissei Pharmaceutical Co., Ltd. | 39.79 Billion JPY | 99.676% |
| Torii Pharmaceutical Co., Ltd. | 13.29 Billion JPY | 99.03% |
| Towa Pharmaceutical Co., Ltd. | 274.75 Billion JPY | 99.953% |
| Fuji Pharma Co., Ltd. | 44.15 Billion JPY | 99.708% |
| Zeria Pharmaceutical Co., Ltd. | 70.7 Billion JPY | 99.818% |
| KYORIN Holdings, Inc. | 46.89 Billion JPY | 99.725% |
| Taiko Pharmaceutical Co.,Ltd. | 7 Billion JPY | 98.158% |
| Daito Pharmaceutical Co.,Ltd. | 25.43 Billion JPY | 99.493% |
| SymBio Pharmaceuticals Limited | 8.14 Billion JPY | 98.416% |
| Mizuho Medy Co.,Ltd. | 3.27 Billion JPY | 96.058% |
| Solasia Pharma K.K. | 673 Million JPY | 80.832% |
| Modalis Therapeutics Corporation | 645.5 Million JPY | 80.016% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 31.38 Billion JPY | 99.589% |
| Sawai Group Holdings Co., Ltd. | 163.99 Billion JPY | 99.921% |
| Cyfuse Biomedical K.K. | 1.01 Billion JPY | 87.245% |
| Toho Holdings Co., Ltd. | 523.98 Billion JPY | 99.975% |
| Koa Shoji Holdings Co.,Ltd. | 6.95 Billion JPY | 98.145% |